Our CEO will make a company presentation and chair a panel at the the 5th Neoantigen Summit Europe
Very are delighted to announce that our CEO Eric Halioua will chair a panel April 28th at the 5th Neoantigen Summit Europe organized by Hanso Wade in Amsterdam, Netherlands from April 26th to April 27th.
The 5th Neoantigen Summit Europe is dedicated to the robust prediction, identification, and validation of neoantigens to create truly individualised cancer therapeutics.
About the event:
Your Comprehensive Guide To Create Truly Personalised Neoantigen Vaccines & Cell-Based Immunotherapies
With COVID-19 bolstering companies developing neoantigen-based mRNA vaccines and neoantigen-specific TCRs gathering momentum, the neoantigen immunotherapy world remains as hot as ever for those dedicated to delivering the promise of truly individualised cancer therapy.
The 5th Neoantigen Summit Europe remains the only industry-led meeting dedicated to the robust prediction, identification and validation of neoantigens to develop potent tumorigenic immune responses.
Find out more here https://ter.li/w1flgy